UA126746C2 - Композиція контрацептива зі зниженими ефектами щодо серцево-судинної системи - Google Patents

Композиція контрацептива зі зниженими ефектами щодо серцево-судинної системи Download PDF

Info

Publication number
UA126746C2
UA126746C2 UAA202005421A UAA202005421A UA126746C2 UA 126746 C2 UA126746 C2 UA 126746C2 UA A202005421 A UAA202005421 A UA A202005421A UA A202005421 A UAA202005421 A UA A202005421A UA 126746 C2 UA126746 C2 UA 126746C2
Authority
UA
Ukraine
Prior art keywords
risk
mte
sos
estetrol
preferably less
Prior art date
Application number
UAA202005421A
Other languages
English (en)
Ukrainian (uk)
Inventor
Мауд Йост
Гладіс Раусін
Гладис Раусин
Original Assignee
Естетра Спрл
Эстетра Спрл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Естетра Спрл, Эстетра Спрл filed Critical Естетра Спрл
Publication of UA126746C2 publication Critical patent/UA126746C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
UAA202005421A 2018-02-07 2019-02-07 Композиція контрацептива зі зниженими ефектами щодо серцево-судинної системи UA126746C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18155571 2018-02-07
EP18160586 2018-03-07
PCT/EP2019/052980 WO2019154899A1 (en) 2018-02-07 2019-02-07 Contraceptive composition with reduced cardiovascular effects

Publications (1)

Publication Number Publication Date
UA126746C2 true UA126746C2 (uk) 2023-01-18

Family

ID=65278388

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA202005421A UA126746C2 (uk) 2018-02-07 2019-02-07 Композиція контрацептива зі зниженими ефектами щодо серцево-судинної системи

Country Status (20)

Country Link
EP (2) EP4140489A1 (https=)
JP (2) JP2021513507A (https=)
KR (1) KR102717921B1 (https=)
CN (2) CN115429806A (https=)
AU (1) AU2019219070B2 (https=)
CA (2) CA3178181A1 (https=)
CL (1) CL2020002017A1 (https=)
EC (1) ECSP20054822A (https=)
GE (2) GEAP202215414A (https=)
IL (1) IL276584B2 (https=)
JO (1) JOP20200169A1 (https=)
MA (1) MA51733A (https=)
NZ (1) NZ766027A (https=)
PH (1) PH12020500601A1 (https=)
PY (1) PY1908892A (https=)
SG (1) SG11202007163WA (https=)
TW (1) TWI845496B (https=)
UA (1) UA126746C2 (https=)
UY (1) UY38075A (https=)
WO (1) WO2019154899A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3701944T3 (da) 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
LT3310346T (lt) 2015-06-18 2021-06-10 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CR20180042A (es) 2015-06-18 2018-05-03 Mithra Pharmaceuticals S A Unidad de dosificación orodispersable que contiene un componente estetrol.
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CN111989105B (zh) 2018-04-19 2024-07-19 埃斯特拉私人有限责任公司 化合物以及它们在缓解绝经相关症状中的用途
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
TWI893101B (zh) * 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
WO2022248733A1 (en) 2021-05-28 2022-12-01 Neuralis Sa Use of estetrol in treatment of respiratory infection diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
EP1390042B1 (en) * 2001-05-23 2007-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
CA2762640A1 (en) * 2009-05-22 2010-11-25 Stefanie Lindemann Medication for oral administration, comprising at least one estrogen and/or at least one gestagen and at least one probiotic bacterial strain
WO2012055840A1 (en) * 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
JP6447931B2 (ja) * 2013-12-12 2019-01-09 ドネスタ バイオサイエンス ビー.ブイ.Donesta Bioscience B.V. エステトロール成分を含有する口腔内崩壊固体単位剤形
CA3041016C (en) 2016-10-28 2023-09-05 Estetra Sprl Method for the management of dysmenorrhea and menstrual pain
KR102712911B1 (ko) * 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법

Also Published As

Publication number Publication date
JP2024009834A (ja) 2024-01-23
CN111683664A (zh) 2020-09-18
JOP20200169A1 (ar) 2020-07-07
IL276584B2 (en) 2024-10-01
CA3178181A1 (en) 2019-08-15
IL276584B1 (en) 2024-06-01
EP3749327A1 (en) 2020-12-16
AU2019219070B2 (en) 2024-12-19
TW202011967A (zh) 2020-04-01
SG11202007163WA (en) 2020-08-28
GEAP202215414A (en) 2022-04-25
ECSP20054822A (es) 2020-12-31
AU2019219070A1 (en) 2020-09-24
IL276584A (en) 2020-09-30
JP7651645B2 (ja) 2025-03-26
NZ766027A (en) 2026-03-27
GEP20227407B (en) 2022-08-25
PH12020500601A1 (en) 2021-05-17
CN115429806A (zh) 2022-12-06
WO2019154899A1 (en) 2019-08-15
KR20200118464A (ko) 2020-10-15
CA3089804A1 (en) 2019-08-15
UY38075A (es) 2019-10-01
MA51733A (fr) 2020-12-16
CL2020002017A1 (es) 2020-12-04
EP4140489A1 (en) 2023-03-01
PY1908892A (es) 2019-10-15
TWI845496B (zh) 2024-06-21
JP2021513507A (ja) 2021-05-27
KR102717921B1 (ko) 2024-10-16

Similar Documents

Publication Publication Date Title
UA126746C2 (uk) Композиція контрацептива зі зниженими ефектами щодо серцево-судинної системи
US20250360147A1 (en) Methods using combined oral contraceptive compositions with reduced cardiovascular effects
JP7177313B2 (ja) 避妊用組成物および避妊方法
Faubion et al. The 2022 hormone therapy position statement of the North American Menopause Society
Klipping et al. Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism
KR102780201B1 (ko) 월경통 및 생리통의 관리방법
Hee et al. Continuous use of oral contraceptives: an overview of effects and side‐effects
JP5128743B2 (ja) ホルモン置換療法用のドロスピレノン
Skouby et al. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 μg ethinyl estradiol combined with 100 μg levonorgestrel
JP7827774B2 (ja) 月経困難症治療用組成物
EA048537B1 (ru) Композиция контрацептива со сниженными эффектами в отношении сердечно-сосудистой системы
HK40081220A (en) Contraceptive composition with reduced cardiovascular effects
Greenblatt The Development of a New Triphasic Oral Contraceptive: The Proceedings of a Special Symposium held at the 10th World Congress on Fertility and Sterility, Madrid July 1980
Pallavee et al. Peripheral arterial disease in a female using high-dose combined oral contraceptive pills
Küçük et al. The effect of low-dose combined oral contraceptive containing 100 ug levonorgestrel on plasma plasminogen activator inhibitor-1 concentrations
Contraceptive et al. PrOVRAL® 21